Table 3.

Univariate Cox analysis of 1-month survival, 12-months survival, and overall survival after diagnosis of AML according to serum YKL-40 levels at day 1 and infections at different times

Covariate (serum YKL-40 day 1)*1-month survival
12-months survival
Overall survival
HR (95% CI)PHR (95% CI)PHR (95% CI)P
Fever and/or antibiotics at day 1
    No (n = 51)1.3 (0.7-2.2)0.411.2 (0.9-1.7)0.271.1 (0.9-1.4)0.39
    Yes (n = 26)1.7 (1.1-2.5)0.0151.7 (1.3-2.3)0.0011.7 (1.2-2.2)0.001
Pneumonia during the study
    No (n = 51)1.6 (1.1-2.3)0.0091.4 (1.1-1.8)0.0061.3 (1.1-1.7)0.016
    Yes (n = 26)2.0 (0.7-5.5)0.152.3 (1.2-4.4)0.0061.3 (0.9-1.8)0.11
Pneumonia and/or septicemia during the study
    No (n = 39)1.6 (1.2-2.3)0.0091.5 (1.1-1.9)0.0061.4 (1.1-1.8)0.005
    Yes (n = 38)1.5 (0.8-2.8)0.241.6 (1.0-2.5)0.0221.2 (0.9-1.5)0.27
  • NOTE: Seventeen deaths within the first month, 44 deaths within the first year, and 69 deaths during the follow-up until December 2004 (n = 77).

  • * Serum YKL-40 levels at day 1 were log-transformed and treated as continuous variables.